I have to be honest, that interview with Dr. Murphy struck me as disappointing and uninspired. While the scientist part of me can appreciate his credentials and his scientific approach to the conversation, the investor part of me is questioning why the company thought this interview was news worthy, as it barely scratched he surface of the potential in this company's pipeline. Would the new CFO be a more articulate and enthusiastic spokesperson for the company? Would the company consider doing another more comprehensive interview with SNN or another outlet to repair the damage done by this?
For instance, he described their other areas or research as "associated with Glaucoma", making it sound like NMUS is a one-trick pony on glaucoma.
Past PR's seem to strongly indicate that the other indications they are pursuing are actually large and separate markets, such as "NB2111 displayed abuse-deterrent activity in a validated animal model of oxycontin addiction." or “We have been able to demonstrate that NB2111 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic." These quotes from past PR's actually indicate much bigger target markets such as: The global pain market, estimated to be more than $30 billion (Transparency Market Research, 2016), is in need of alternatives to opioid-based medicines," commented Brian Murphy, MD, MBA, the Nemus CEO and Chief Medical Officer.
He doesn't even do a very good job of describing why a "prodrug" formulation is so much better than raw medical marijuana other than to say "patented", I would have appreciated if he got more detailed about the ability to isolate the medicinal effects of the hundreds of different individual compounds and concentrate those constituents for a more efficacious treatment than could be provided by raw plant material, or concentrates.
"Our houses are such unwieldy property that we are often imprisoned rather than housed in them." - Henry David Thoreau, Walden: Economy, 1854
